CLINICAL TRIALS PROFILE FOR VIREAD
✉ Email this page to a colleague
All Clinical Trials for Viread
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00051831 ↗ | Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults | Completed | AIDS Clinical Trials Group | N/A | 2003-10-01 | HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV. |
| NCT00051831 ↗ | Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 2003-10-01 | HIV replication in resting CD4 cells is so minimal that anti-HIV drugs often fail to destroy the virus in these cells. Enfuvirtide, also known as T-20, is a type of anti-HIV drug called a fusion inhibitor. The purpose of this study is to test the ability of a T-20-enhanced treatment regimen to decrease the number of resting CD4 cells that become infected with HIV. |
| NCT00074581 ↗ | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Completed | HIV Prevention Trials Network | Phase 3 | 2005-02-01 | This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not. |
| NCT00074581 ↗ | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2005-02-01 | This study will determine whether anti-HIV drugs can prevent the sexual transmission of HIV among couples in which one partner is HIV infected and the other is not. |
| NCT00078182 ↗ | Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia | Withdrawn | Kirby Institute | Phase 2/Phase 3 | 1969-12-31 | Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection. This study will determine if taking a tenofovir DF tablet every day is safe and effective in preventing HIV infection. Participants in the study will be sex workers in Phnom Penh, Cambodia. |
| NCT00078182 ↗ | Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia | Withdrawn | NCHADS - Ministry of Health of Cambodia | Phase 2/Phase 3 | 1969-12-31 | Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection. This study will determine if taking a tenofovir DF tablet every day is safe and effective in preventing HIV infection. Participants in the study will be sex workers in Phnom Penh, Cambodia. |
| NCT00078182 ↗ | Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2/Phase 3 | 1969-12-31 | Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection. This study will determine if taking a tenofovir DF tablet every day is safe and effective in preventing HIV infection. Participants in the study will be sex workers in Phnom Penh, Cambodia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Viread
Condition Name
Clinical Trial Locations for Viread
Trials by Country
Clinical Trial Progress for Viread
Clinical Trial Phase
Clinical Trial Sponsors for Viread
Sponsor Name
